Contracts › 75N93020C00020
75N93020C00020: To Advance a Promising, Small-Molecule Compound CRS0540 to Ind Filing and Through Phase I Clinical Studies.
Awarded to Crestone, Inc. by National Institutes of Health (NIH).
$22.0Mobligated
$27.0Mpotential value
31 January 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93020C00020 |
|---|---|
| Awardee | Crestone, Inc. |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | CO |
| Offers received | 12 |
| Period of performance | 01 July 2020 to 31 January 2027 |
| Potential end | 31 January 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record